Characterization of Human Autoantibody Titers After Central Nervous System Insult



Status:Recruiting
Conditions:Brain Cancer, Hospital, Neurology
Therapuetic Areas:Neurology, Oncology, Other
Healthy:No
Age Range:18 - Any
Updated:11/3/2018
Start Date:May 2015
End Date:May 2022
Contact:Gregory WJ Hawryluk, MD, Ph.D.
Email:gregory.hawryluk@hsc.utah.edu
Phone:801-581-6908

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The aim of the study is to quantitate Central Nervous System (CNS) autoantibody development
in human blood using ELISA after human brain injury, spinal cord injury, and intra-axial
brain surgeries.

Study Objectives:

We aim to:

1. Quantitate CNS autoantibody development in human blood using ELISA after human brain
injury, spinal cord injury, and intra-axial brain surgeries. We also aim to characterize
the temporal course of this response.

2. Characterize how CNS autoantibody levels correlate with specific injury patterns as well
as radiographic and clinical measures of injury severity.

3. Determine how intercurrent infection and a history of prior CNS insult affects the
temporal course and magnitude of autoantibody production.

Inclusion Criteria:

- Have a severe traumatic brain injury

- Have spinal cord injury ASIA grade A, B or C

- Undergoing resection of intra-axial brain tumors

Exclusion Criteria:

- Participant who is pregnant
We found this trial at
1
site
University Of Utah Hospital
Salt Lake City, Utah 84132
Phone: 801-581-6908
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials